Company Overview and News

 
Savings and Loan Industry Outlook: Near-Term Prospects Look Bleak

2018-09-14 zacks
Over the last few years, an improving domestic economy and rising demand for residential mortgages have favored the U.S. savings and loan industry. Rising income of Americans, along with relatively low interest rates, has supported the housing market by enhancing demand for residential mortgages. This has helped the industry grow over this period. In fact, lesser regulatory supervision and an improving housing market, though at a slow pace, are anticipated to keep driving the industry’s growth in the upcoming quarters too.
BANR GSBC FDEF RVSB RVSP NWBI

18
The Zacks Analyst Blog Highlights: Riverview, BG, Natural Grocers, Summer Infant and Hallmark

2018-09-11 zacks
Chicago, IL –September 11, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Riverview Bancorp, Inc. (RVSB - Free Report) , BG Staffing, Inc. (BGSF - Free Report) , Natural Grocers by Vitamin Cottage, Inc.
HALL WCG BGSF ALK CME SUMR RVSB MS GM MPX RVSP 7018 NGVC TLRD

 
RVSP / RIVERVIEW BANCORP INC FORM 10-Q (Quarterly Report)

2018-08-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 &
RVSP

 
RVSP / RIVERVIEW BANCORP INC FORM 8-K (Current Report)

2018-07-27 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,
RVSP

 
RVSP / RIVERVIEW BANCORP INC FORM 8-K (Current Report)

2018-07-26 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
RVSP

 
Riverview Bancorp Increases Quarterly Cash Dividend

2018-07-03 globenewswire
VANCOUVER, Wash., July 03, 2018 (GLOBE NEWSWIRE) -- Riverview Bancorp, Inc. (Nasdaq:RVSB) (“Riverview” or the “Company”) today announced its Board of Directors increased its quarterly cash dividend to $0.035 per share. The dividend will be payable July 24, 2018, to shareholders of record July 13, 2018. Based on the current share price, the annualized dividend yield is 1.61%.
RVSB RVSP

10
OptimumBank Holdings, Inc. Strengthens Board of Directors with the Appointment of Mr. Heng Fai Ambrose Chan

2018-06-28 globenewswire
FORT LAUDERDALE, FL, June 28, 2018 (GLOBE NEWSWIRE) -- OptimumBank Holdings, Inc., the parent company of OptimumBank (www.OptimumBank.com) (NASDAQ: OPHC), a bank that provides a range of consumer and commercial banking services to individuals and businesses, is pleased to announce the appointment of Mr. Heng Fai Ambrose Chan (Mr. Chan) as a member to its Board of Directors. Mr. Chan is an accomplished business executive based in Singapore.
HCT SPXCY OPHC CGHLY SPXCF 5H0 RVSB RVSP CGHOF S68 0384

 
RVSP / RIVERVIEW BANCORP INC DEF 14A

2018-06-15 sec.gov
Proxy Statement Pursuant to S
RVSP

 
RVSP / RIVERVIEW BANCORP INC FORM 10-K (Annual Report)

2018-06-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
RVSP

 
RVSP / RIVERVIEW BANCORP INC FORM 8-K (Current Report)

2018-05-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
RVSP

 
RVSP / RIVERVIEW BANCORP INC FORM 8-K (Current Report)

2018-05-01 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
RVSP

 
RVSP / RIVERVIEW BANCORP INC FORM 8-K (Current Report)

2018-04-12 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,
RVSP

 
RVSP / RIVERVIEW BANCORP INC FORM 8-K (Current Report)

2018-04-03 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washing
RVSP

1
Riverview Bancorp Declares Quarterly Cash Dividend

2018-04-02 globenewswire
VANCOUVER, Wash., April 02, 2018 (GLOBE NEWSWIRE) -- Riverview Bancorp, Inc. (Nasdaq:RVSB) (“Riverview” or the “Company”) today announced its Board of Directors declared a quarterly cash dividend of $0.03 per share. The dividend will be payable April 24, 2018, to shareholders of record April 13, 2018. Based on the current share price, the annualized dividend yield is 1.29%.
RVSB RVSP

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...